Corbin Ballam, DO
Internal Medicine · Tucson, AZNPI 1205282894
Payments from drug & device makers
Across 121 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$283
- AbbVie$192
- AstraZeneca$175
- Penumbra, Inc.$171
- Teva Pharmaceuticals USA, Inc.$128
- GSK$128
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,460100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $283 |
| AbbVie | 11 | $192 |
| AstraZeneca | 10 | $175 |
| Penumbra, Inc. | 1 | $171 |
| Teva Pharmaceuticals USA, Inc. | 6 | $128 |
| GSK | 7 | $128 |
| Amgen | 7 | $125 |
| Astellas Pharma US Inc | 5 | $112 |
| Johnson & Johnson | 6 | $101 |
| Bayer | 6 | $95 |
| Pfizer | 5 | $88 |
| Lilly USA, LLC | 5 | $84 |
| Novartis | 4 | $81 |
| Sumitomo Pharma America, Inc. | 3 | $80 |
| Almatica Pharma LLC | 4 | $79 |
| Exact Sciences | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 2 | $63 |
| Novo Nordisk | 3 | $60 |
| Boehringer Ingelheim | 2 | $42 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Merck | 2 | $35 |
| Radius Health, Inc. | 1 | $29 |
| Medtronic | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$171
How this compares
$2,460 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 151 | $242,798 |
| EliquisApixaban | 143 | $165,745 |
| XareltoRivaroxaban | 114 | $154,908 |
| JardianceEmpagliflozin | 123 | $150,222 |
| CreonLipase/Protease/Amylase | 38 | $92,754 |
| FarxigaDapagliflozin Propanediol | 100 | $90,390 |
| MounjaroTirzepatide | 47 | $63,003 |
| TrulicityDulaglutide | 26 | $43,388 |
| ProliaDenosumab | 24 | $40,545 |
| JanuviaSitagliptin Phosphate | 24 | $38,687 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $36,023 |
| RybelsusSemaglutide | 13 | $19,944 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $19,853 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $19,570 |
| MyrbetriqMirabegron | 17 | $18,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $60 | $262,742164 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $42 | $177,219160 claims |
| PfizerEliquis | $88 | $165,745143 claims |
| Johnson & JohnsonXarelto | $101 | $154,908114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $175 | $109,960133 claims |
| Lilly USA, LLCMounjaro, Trulicity | $84 | $106,39173 claims |
| AbbVieCreon, Synthroid | $192 | $97,099117 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $128 | $61,370107 claims |
| MerckJanuvia, Janumet Xr | $35 | $45,67036 claims |
| AmgenProlia | $125 | $40,54524 claims |
| Astellas Pharma US IncMyrbetriq | $112 | $18,38817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Tucson
- Robert MutterperlTucson$5.3M
- Nebojsa SkrepnikTucson$4.7M
- Franz RischardTucson$3.7M
- Girish KaramchandaniTucson$2.9M
- Siddharth SinghalTucson$1.3M
- Rajesh JanardhananTucson$983K
- Carl DienerTucson$750K
- Roxana RodriguezTucson$547K
- Mona SelejTucson$440K
- Muhammad HusnainTucson$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.